Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bemdaneprocel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | ACTIVE_COMPARATOR | Bemdaneprocel will be administered on Day 0 |
| Group B | SHAM_COMPARATOR | Sham surgery will be performed on Day 0 |
| Name | Type | Description |
|---|---|---|
| bemdaneprocel | BIOLOGICAL | Investigational cell therapy comprising midbrain dopaminergic neuron progenitors derived from human embryonic stem cells |
| Sham surgery | PROCEDURE | Sham surgery will be performed on Day 0 |
Inclusion Criteria: * Diagnosis of clinically established PD as defined by the International Parkinson and Movement Disorders Society * Individual of any sex ≥45 to ≤75 years of age at informed consent * Robust and clear response to DA therapy as defined by MDS-UPDRS Part III * ≥4 and \<12 years fr...
Bemdaneprocel is an investigational cell therapy being studied for the treatment of Parkinson's Disease (PD). It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities. The therapy is being evaluated in adults with Parkinson's Disease to assess its efficacy and safety.
Bemdaneprocel is a cell therapy, classified under the -cel (cell tx) target class. As a cell-based treatment, it is designed to replace or repair damaged cells in the brain associated with Parkinson's Disease. The specific molecular target is not disclosed in the available information.
Bemdaneprocel is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational cell therapy for Parkinson's Disease.
Bemdaneprocel is currently in Phase 3 clinical development. It is an investigational therapy, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 3 trial is actively recruiting participants to further evaluate the treatment's efficacy and safety in adults with Parkinson's Disease.
Bemdaneprocel is being studied in a Phase 3 clinical trial registered as NCT06944522. This randomized, double-blind, active-controlled study is investigating the efficacy and safety of bemdaneprocel in adults with Parkinson's Disease. The trial is recruiting participants in the United States, Australia, and Canada, with a planned enrollment of 102 participants.
Bemdaneprocel is a distinct investigational cell therapy developed by Bayer AG. No alternative names for this drug have been identified in the available information. It is being studied specifically for Parkinson's Disease and is currently in Phase 3 clinical trials.